tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Ascendis Pharma Submits EMA Application for Achondroplasia Treatment

Story Highlights
  • Ascendis Pharma specializes in therapies for rare diseases using its TransCon technology.
  • The company applied for EMA approval of TransCon CNP for achondroplasia treatment on October 8, 2025.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Ascendis Pharma Submits EMA Application for Achondroplasia Treatment

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Ascendis Pharma ( (ASND) ) just unveiled an announcement.

On October 8, 2025, Ascendis Pharma announced the submission of a Marketing Authorisation Application to the European Medicines Agency for TransCon CNP, a treatment for children with achondroplasia. This investigational prodrug aims to provide continuous inhibition of the FGFR3 pathway, potentially improving the quality of life for individuals with this rare genetic condition.

The most recent analyst rating on (ASND) stock is a Buy with a $240.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.

Spark’s Take on ASND Stock

According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.

Ascendis Pharma’s stock score is driven by strong earnings call highlights and positive technical indicators. However, financial performance and valuation concerns due to ongoing losses and reliance on debt financing weigh down the overall score.

To see Spark’s full report on ASND stock, click here.

More about Ascendis Pharma

Ascendis Pharma A/S is a biopharmaceutical company based in Denmark, specializing in the development of innovative therapies for rare diseases. The company focuses on creating prodrugs designed to improve patient outcomes through its proprietary TransCon technology platform.

Average Trading Volume: 468,150

Technical Sentiment Signal: Buy

Current Market Cap: $12.77B

For a thorough assessment of ASND stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1